Surmodics Buys Alta Biomed to Boost Advanced Medical Device Coatings
Eden Prairie, Thursday, 1 October 2026.
Surmodics has acquired Alta Biomed, expanding its medical coating portfolio with an FDA-cleared technology used for complex implants like brain-computer interfaces, while adding specialized blood-testing capabilities.
Transaction Overview and Timeline
Surmodics Inc. (NASDAQ: SRDX) officially announced the acquisition of Alta Biomed’s business assets on 1 October 2026, marking a significant expansion in the medical device technology sector [1]. The transaction secures Alta Biomed’s proprietary assets, including its specialized testing capabilities and surface modification technologies, effective as of the report date [2]. This strategic move integrates Alta Biomed’s operations into Surmodics’ broader organization, with the Carlsbad, California facility continuing operations under the new ownership structure [1]. The acquisition is positioned to enhance Surmodics’ ability to serve complex medical device markets, including neuromodulation and structural heart technologies [2].
Proprietary Technology and Regulatory History
Central to the acquisition is Alta Biomed’s PzF™ thin-film surface modification technology, which boasts over 20 years of medical application history [1]. The technology portfolio includes six FDA clearances and one Premarket Approval (PMA) specifically for use in cardiovascular and embolization technologies [2]. These regulatory milestones demonstrate a established track record for the technology in blood- and tissue-contacting device applications [1]. The PzF™ technology is compatible with diverse substrates such as metals, polymers, medical textiles, and tissue, supporting current commercial applications in stents, grafts, and catheters [2].
Operational Expansion and Leadership
The acquisition establishes a new West Coast presence for Surmodics through Alta Biomed’s Carlsbad facility, which provides specialized hemocompatibility assessment and dynamic human blood loop testing [1]. Chris Nocera, formerly VP of Engineering at Alta Biomed, will lead the Carlsbad location as the company integrates the new capabilities into the broader organization [2]. Charlie Olson, President of Surmodics Coatings, Biomaterials and Catheter Technologies, noted that engineers require a broader range of surface technology options to address increasingly complex blood-contacting applications [1]. Integration plans indicate that Surmodics will continue existing Alta Biomed programs while leveraging the added scale to reach more patients with advanced coating technologies [2].